Genfit S.A.

3.68
0.01 (0.27%)
At close: Apr 25, 2025, 10:07 AM
0.27%
Bid 3.64
Market Cap 183.5M
Revenue (ttm) 111.55M
Net Income (ttm) 37.43M
EPS (ttm) 0.43
PE Ratio (ttm) 8.56
Forward PE -17.55
Analyst Buy
Ask 3.83
Volume 275
Avg. Volume (20D) 14,045
Open 3.86
Previous Close 3.67
Day's Range 3.68 - 3.86
52-Week Range 2.55 - 6.42
Beta 1.23

About GNFT

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat ...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2019
Employees 169
Stock Exchange NASDAQ
Ticker Symbol GNFT
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for GNFT stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 253.26% from the latest price.

Stock Forecasts
7 months ago
+15.51%
GENFIT shares are trading higher. The company repo... Unlock content with Pro Subscription